Navigation Links
Diabetes Spectrum Reports a Study Assessing the i-port(R) Injection Port for Administration of Insulin
Date:9/17/2008

Device a "Viable Alternative" to Standard Injections - 69% of Patients Report i-port(R) is Helpful in the Management of Their Diabetes

AUSTIN, Texas, Sept. 17 /PRNewswire/ -- In a clinical trial comparing the i-port(R) (a small, disposable injection port about the size of a quarter) with standard injections in people with type 1 and type 2 diabetes, participants' differences in glycosylated albumin was not significantly different. The new data appeared in an article published in the current issue (Summer, 2008) of Diabetes Spectrum, a peer-reviewed journal of the American Diabetes Association. Glycosylated albumin is a direct measure of short term glucose in blood protein. Based on these results, the authors conclude that the utility and efficacy of administering multiple doses of insulin through a single i-port(R) device is a viable alternative to standard injections. View the complete abstract and/or purchase the feature article at http://spectrum.diabetesjournals.org/cgi/content/abstract/21/3/197.

"Our study demonstrates that delivering insulin via the i-port(R) provides the same therapeutic benefits as standard injections," said lead investigator Dr. Thomas Blevins of Texas Diabetes and Endocrinology in Austin, Texas. "This is especially significant for people with diabetes who struggle with adherence and need an alternative to the multiple daily skin punctures required by standard injections."

The prospective, randomized, controlled, open-label crossover study enrolled 74 patients with diabetes being treated with daily insulin injections at five trial sites. Participants were randomly assigned to two of three injection treatment regimens including standard injection, injecting through a single i-port(R) device, and injecting through two separate i-port(R) devices with each regimen lasting three weeks. Patients using the single i-port(R) regimen injected both regular human or rapid-acting insulin and LANTUS(R) through the same device (separating the dose of LANTUS(R) from the regular human or rapid acting insulin by at least 60 minutes). Participants using the dual i-port(R) regimen injected each type of insulin through two separate devices. Participants were evaluated by measurements of glycosylated albumin and study questionnaires. The results were not significantly different between the three treatment regimens (P = 0.99 for standard injection vs. single i-port(R) and P = 0.97 for single i-port(R) vs. dual i-port(R)). Fifty of 72 participants (69.4%) reported that the i-port(R) was useful and helpful in the management of their diabetes.

ABOUT the i-port(R) Injection Port

The i-port(R) Injection Port is a prescription only device cleared by the FDA in September 2005, for use by people requiring multiple daily, subcutaneous injections of physician-prescribed medications, including insulin. The i-port(R) may be a helpful treatment delivery tool for anyone who wants to minimize the intrusion of daily injections.

The i-port(R) should not be worn for longer than 72 hours. The most serious risks when using the i-port(R) include infection and the potential for poor medication delivery if not properly applied. For people with diabetes, the poor medication delivery may result in abnormally high or low blood sugar levels. If you experience these or any other problems when using the i-port(R), tell your doctor.

About Patton Medical Devices

Headquartered in Austin, Texas, Patton Medical Devices is the manufacturer of the i-port(R) Injection Port. For people taking injection therapy who want to minimize the intrusion of injections on daily life, the i-port(R) is the only product of its kind conceived by a person with diabetes that offers a simple, convenient way to eliminate the need to puncture the skin with each dose of medication. The i-port(R) lets patients focus on living their lives instead of the challenges associated with the next shot. For more information about Patton Medical Devices, its products and services, visit http://www.i-port.com or http://www.pattonmd.com.

Contacts: Doug Hochstedler Nicole Carp

212-798-9724 212-798-9753

doug.hochstedler@offspringpr.com nicole.carp@offspringpr.com


'/>"/>
SOURCE Patton Medical Device
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Session highlights of the 1st World Congress on Interventional Therapies for Type 2 Diabetes
2. Weight-Loss Surgery Weighed as Diabetes Rx
3. American Diabetes Association Announces New Latino Diabetes Toolkit
4. American Diabetes Association Kicks 0ff Hispanic Heritage Month
5. Community-based diabetes prevention program shows promise
6. Once-Weekly Diabetes Drug Boosts Blood Sugar Control
7. Early trigger for type-1 diabetes found in mice, Stanford scientists report
8. Endocrinologists and surgeons join forces to fight type 2 diabetes
9. Nutraceuticals could prevent diabetes
10. Amylin Pharmaceuticals Diabetes Drug Byetta the Focus of California Lawsuit
11. Independence Blue Cross Signs on as Presenting Sponsor of American Diabetes Associations Step Out: Walk to Fight Diabetes in Philadelphia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... ... A quote from Dr. Edward Hallowell, host of CRN International’s “Distraction” podcast ... glimpse into the mind of those people with ADHD. , Dr. Hallowell, a child ... people with ADHD as having “Ferrari engines for a brain, with bicycle brakes.” , ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Cliff ... located in South Lyon, Dewitt, Williamston, East Lansing, Ann Arbor, and Farmington Hills, ... treatment for a brain tumor. , Jason Bauer and his family are longtime ...
(Date:12/7/2016)... ... December 07, 2016 , ... A. Kevin Spann Insurance, a New York-based firm ... Boroughs, is launching a charity drive to raise funds that will benefit the Marine ... of marines and Navy FMF Corpsmen. Working closely with the MCL, the A. Kevin ...
(Date:12/7/2016)... ... December 07, 2016 , ... Delete® - Tattoo Removal and Laser Salon Offers ... Season. Save Up To 33% Off Botox® and Juvederm® Products Now Through December 31, ... with Delightful Deals on Botox® and Juvederm® just in time for the ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... BOC Business Brilliance Awards under the Best New Product Launch category. Gensuite’s entry ... through user experience. , BOC Global Events & Training Group is a professional ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... -- According to responses from U.S. oncologists that participated in ... with non-small cell lung cancer (NSCLC), treatment decisions are made ... status. The findings of the survey were presented today as ... ) at the 2016 World Conference on Lung Cancer (WCLC) ... survey results revealed an overall high rate of EGFR mutation ...
(Date:12/7/2016)... ALTO, Calif. , Dec. 7, 2016  Varian ... an update to its previously announced plans to separate ... be executed via a tax-free distribution to Varian stockholders ... stand-alone public company that will hold the Imaging Components ... expected to be executed by the end of January ...
(Date:12/7/2016)... , Dec. 7, 2016 Boehringer ... trial in patients with unresectable malignant pleural mesothelioma ... (PFS). The data, presented at the 17 th ... Vienna , showed nintedanib plus ... placebo plus pemetrexed/cisplatin, with a significantly improved PFS ...
Breaking Medicine Technology: